GEOVAX LABS INC (GOVX)
US3736786068 - Common Stock
Taking everything into account, GOVX scores 0 out of 10 in our fundamental rating. GOVX was compared to 565 industry peers in the Biotechnology industry. Both the profitability and financial health of GOVX have multiple concerns. GOVX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year GOVX has reported negative net income.
GOVX had a negative operating cash flow in the past year.
GOVX had negative earnings in each of the past 5 years.
In the past 5 years GOVX always reported negative operating cash flow.
1.2 Ratios
GOVX has a worse Return On Assets (-657.26%) than 98.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -657.26% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-160.62%
ROA(5y)-203.16%
ROE(3y)-309.67%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GOVX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GOVX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GOVX has been increased compared to 1 year ago.
GOVX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for GOVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
GOVX has an Altman-Z score of -59.53. This is a bad value and indicates that GOVX is not financially healthy and even has some risk of bankruptcy.
GOVX has a worse Altman-Z score (-59.53) than 94.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -59.53 |
ROIC/WACCN/A
WACC10.28%
2.3 Liquidity
GOVX has a Current Ratio of 0.60. This is a bad value and indicates that GOVX is not financially healthy enough and could expect problems in meeting its short term obligations.
GOVX's Current ratio of 0.60 is on the low side compared to the rest of the industry. GOVX is outperformed by 92.34% of its industry peers.
A Quick Ratio of 0.60 indicates that GOVX may have some problems paying its short term obligations.
GOVX has a Quick ratio of 0.60. This is amonst the worse of the industry: GOVX underperforms 91.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.6 | ||
| Quick Ratio | 0.6 |
3. Growth
3.1 Past
GOVX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -105.95%.
The Revenue for GOVX has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-105.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.7%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, GOVX will show a very strong growth in Earnings Per Share. The EPS will grow by 25.10% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y71.01%
EPS Next 2Y40.13%
EPS Next 3Y25.1%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
GOVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GOVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as GOVX's earnings are expected to grow with 25.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.13%
EPS Next 3Y25.1%
5. Dividend
5.1 Amount
No dividends for GOVX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GEOVAX LABS INC
NASDAQ:GOVX (11/12/2024, 8:07:24 PM)
Premarket: 2.89 -0.36 (-11.08%)3.25
+0.11 (+3.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap27.69M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -657.26% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.6 | ||
| Quick Ratio | 0.6 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-105.95%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y71.01%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y